Compare TEI & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEI | XBIT |
|---|---|---|
| Founded | 1993 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.9M | 73.2M |
| IPO Year | N/A | 2015 |
| Metric | TEI | XBIT |
|---|---|---|
| Price | $6.25 | $2.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 146.0K | 21.4K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 10.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.56 | $2.09 |
| 52 Week High | $7.00 | $3.61 |
| Indicator | TEI | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 46.32 |
| Support Level | $6.19 | $2.15 |
| Resistance Level | $6.48 | $2.49 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 40.74 | 34.78 |
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.